Lipid Panel Interpreter

Enter your lipid panel results to get a per-component interpretation — Total Cholesterol, LDL, HDL, Triglycerides, and Non-HDL — with NCEP ATP III and ACC/AHA 2018 cutoffs, plus context on which numbers matter most for different populations.

Unit system

Sex (adjusts HDL cutoffs)

Total Cholesterol

mg/dL

HDL Cholesterol

mg/dL

LDL Cholesterol

mg/dL

Triglycerides

mg/dL

Age (optional, context only)

Total Cholesterol

—

LDL Cholesterol

—

HDL Cholesterol

—

Triglycerides

—

Non-HDL Cholesterol (auto)

—

Cutoffs from NCEP ATP III and the ACC/AHA 2018 cholesterol guideline. Reference ranges vary across laboratories; cardiovascular risk should be assessed with a validated calculator (ACC/AHA Pooled Cohort Equations or SCORE2) and discussed with your doctor.

How to Read a Lipid Panel

A standard lipid panel reports four numbers — Total Cholesterol, HDL, LDL, and Triglycerides — plus typically a calculated Non-HDL. Each one tells you something different, and the right question is not "is this number normal?" but "is this number in an appropriate range for my cardiovascular risk profile?". Population reference ranges published by NCEP ATP III in 2001 are still broadly used to frame what a result means, but the treatment goals derived from them have shifted considerably with the ACC/AHA 2018 cholesterol guideline and the ESC/EAS 2019 European dyslipidaemia guidelines, both of which emphasise LDL reduction in higher-risk groups.

NCEP ATP III Reference Bands

Component	Optimal	Near Optimal / Normal	Borderline	High	Very High
Total Cholesterol	< 200 mg/dL < 5.2 mmol/L	—	200 – 239 5.2 – 6.2	≥ 240 ≥ 6.2	—
LDL Cholesterol	< 100 < 2.6	100 – 129 2.6 – 3.3	130 – 159 3.4 – 4.1	160 – 189 4.1 – 4.9	≥ 190 ≥ 4.9
HDL (men)	≥ 60 ≥ 1.55	40 – 59 1.0 – 1.54	—	< 40 < 1.0	—
HDL (women)	≥ 60 ≥ 1.55	50 – 59 1.3 – 1.54	—	< 50 < 1.3	—
Triglycerides	< 150 < 1.7	—	150 – 199 1.7 – 2.25	200 – 499 2.26 – 5.6	≥ 500 ≥ 5.6
Non-HDL (TC − HDL)	< 130 < 3.4	130 – 159 3.4 – 4.1	160 – 189 4.2 – 4.9	190 – 219 4.9 – 5.7	≥ 220 ≥ 5.7

Values in mg/dL (top) and mmol/L (bottom). Sources: NCEP ATP III Expert Panel, Circulation 2002; ACC/AHA 2018 Cholesterol Guideline (Grundy SM et al., Circulation 2019); ESC/EAS 2019 Dyslipidaemia Guidelines.

Which Number Matters Most?

The honest answer is: it depends on who you are.

For an average-risk adult: LDL and non-HDL are the main targets, alongside overall lifestyle risk.
For someone with metabolic syndrome, pre-diabetes, or type 2 diabetes: Triglycerides, the TG/HDL ratio, non-HDL, and ideally apoB matter more than LDL alone. LDL-C can look deceptively normal when LDL particles are small, dense, and atherogenic. apoB directly counts atherogenic particles.
For someone with very high LDL (above 190 mg/dL / 4.9 mmol/L): Consider familial hypercholesterolaemia. Even at young ages and in the absence of other risk factors, the ACC/AHA 2018 guideline generally recommends treatment.
For someone with triglycerides above 500 mg/dL (5.6 mmol/L): Pancreatitis risk becomes the dominant clinical concern. Treatment focuses on reducing triglycerides with dietary change, alcohol reduction, fibrates, omega-3s, and addressing contributing factors.
For someone with prior cardiovascular events: Much lower LDL targets apply (often <70 mg/dL or even <55 mg/dL depending on guideline), and lipid-lowering therapy is usually indicated regardless of baseline level.

Beyond the Basic Panel

Several additional lipid measurements and related markers can refine risk assessment beyond the standard four numbers:

Apolipoprotein B (apoB) — counts atherogenic lipoprotein particles directly. Increasingly regarded as superior to LDL-C in metabolic syndrome, diabetes, and mixed dyslipidaemia.
Lipoprotein(a), or Lp(a) — a genetically determined LDL-like particle with thrombogenic properties. Independent cardiovascular risk factor. Typically measured once in a lifetime.
High-sensitivity CRP (hs-CRP) — a marker of low-grade inflammation; JUPITER trial showed cardiovascular benefit from statin therapy in patients with normal LDL but elevated hs-CRP.
Lipoprotein subfractions (LDL particle number, size) — research tools rather than first-line clinical tests, but useful in specific contexts.
Coronary artery calcium (CAC) score — a CT-based imaging test that directly visualises atherosclerotic burden; helpful when risk-based treatment decisions are unclear.

Fasting vs Non-Fasting

Both the 2016 EAS/EFLM consensus and the 2019 ESC/EAS guidelines endorse non-fasting lipid panels for most routine assessment. HDL, Total, and Non-HDL change minimally after a meal; triglycerides rise modestly. Fasting is still typically preferred when the specific question is triglyceride evaluation (e.g., assessing pancreatitis risk), when using Friedewald's LDL calculation, or when following an established monitoring protocol. Always follow your lab's specific instructions.

What This Tool Doesn't Do

This tool interprets each component against reference cutoffs. It does not calculate 10-year ASCVD risk, because that requires age, sex, race, systolic blood pressure, blood pressure treatment, smoking, and diabetes alongside lipids. For formal risk stratification, use the ACC/AHA Pooled Cohort Equations (US) or SCORE2 (Europe) with your doctor, who can also translate the output into treatment decisions. Lipid interpretation is a starting point for that conversation, not a replacement for it.

Frequently Asked Questions

What is a normal lipid panel?

Per the long-standing NCEP ATP III framework used by most laboratories, Total Cholesterol below 200 mg/dL (5.2 mmol/L) is desirable, LDL below 100 mg/dL (2.6 mmol/L) is optimal, HDL above 40 mg/dL (1.0 mmol/L) in men and above 50 mg/dL (1.3 mmol/L) in women is adequate with ≥60 mg/dL (1.55 mmol/L) considered protective, and Triglycerides below 150 mg/dL (1.7 mmol/L) is normal. These are population reference bands, not individualised treatment targets — treatment goals depend on global cardiovascular risk.

What is Non-HDL cholesterol and why does it matter?

Non-HDL cholesterol is Total Cholesterol minus HDL. It captures all atherogenic lipoproteins — LDL, IDL, VLDL remnants, and Lp(a) — in one number, rather than just LDL. NCEP ATP III and subsequent guidelines use non-HDL as a secondary target, with a commonly cited goal of below 130 mg/dL (3.4 mmol/L) for average-risk adults and lower goals for higher-risk groups. Non-HDL is particularly useful when triglycerides are elevated because the Friedewald LDL estimate becomes less reliable in that setting.

Should I fast before a lipid panel?

Both the 2016 European Atherosclerosis Society / European Federation of Clinical Chemistry consensus statement and the 2019 ESC/EAS guidelines endorse non-fasting lipid panels for most routine assessment — HDL, Total, and Non-HDL are minimally affected by a recent meal. Fasting is still typically preferred when triglycerides are the specific question (for example, evaluating pancreatitis risk at very high levels), when making Friedewald LDL calculations, or when following an established monitoring pattern. Follow your lab's specific instructions; many now accept non-fasting samples.

At what triglyceride level is there pancreatitis risk?

Triglycerides above 500 mg/dL (5.6 mmol/L) are classified as very high and are associated with a rising risk of acute pancreatitis, with risk increasing sharply above 1000 mg/dL (11.3 mmol/L). Severe hypertriglyceridaemia is typically treated aggressively with dietary restriction, fibrates or omega-3 fatty acids, and by addressing contributors such as alcohol, diabetes, and certain medications. Values above 500 mg/dL warrant prompt medical review; values above 1000 mg/dL often warrant urgent evaluation.

What is apoB and is it better than LDL?

Apolipoprotein B (apoB) is the structural protein on every atherogenic lipoprotein particle — LDL, IDL, VLDL and Lp(a) each carry exactly one apoB. Measuring apoB therefore gives a direct count of atherogenic particles, rather than the cholesterol mass carried by them. Many lipidologists consider apoB superior to LDL-C for risk assessment, particularly in people with metabolic syndrome, type 2 diabetes, or mixed dyslipidaemia where LDL cholesterol and LDL particle number can diverge. ACC/AHA 2018 and ESC/EAS 2019 both recognise apoB as a reasonable alternative or addition to non-HDL for risk stratification in selected patients.

Why doesn't this tool calculate ASCVD risk?

Calculating 10-year atherosclerotic cardiovascular disease (ASCVD) risk requires more than lipids — it depends on age, sex, race, systolic blood pressure, whether blood pressure is treated, smoking status, and diabetes status. Both the ACC/AHA Pooled Cohort Equations and the European SCORE2 framework combine all of these inputs. We intentionally kept this tool focused on lipid component interpretation rather than running a full cardiovascular risk calculation, because a small tool is not the right place to do a clinical risk score. For formal ASCVD risk, use a validated calculator with your doctor, who can also discuss how your full risk profile translates into treatment decisions.

Related on Health3

Cholesterol Ratio Calculator Blood Pressure Category Checker Blood Test Unit Converter HOMA-IR Calculator Cardiovascular Health Metabolic Health Understanding Cholesterol Blood Tests Tracking High Cholesterol Statin Users

Medical Disclaimer: This lipid panel interpreter is provided for educational and informational purposes only. Reference cutoffs reflect commonly used consensus bands and do not replace guideline-based cardiovascular risk assessment. Treatment decisions depend on overall risk, not isolated lipid values. This tool does not constitute medical advice and is not a substitute for consultation with a qualified healthcare provider. Always discuss your lipid panel results with your doctor.

Track Your Blood Work with Health3

Health3 tracks your full lipid panel alongside metabolic markers, blood pressure, and more — with trends, ratios, and plain-language explanations of what each number means.